Alzheimer’s disease expert Richard S. Isaacson, MD, explores strategies for care collaboration to optimize care for patients with Alzheimer’s disease (AD), the importance of determining patient-specific pharmacologic treatment approaches for patients with AD, and implementing approaches for effective communication with patients and caregivers surrounding AD diagnosis and management.
Dermatology expert Linda Stein Gold, MD, explores the rationale for Janus kinase (JAK) inhibition in atopic dermatitis (AD), clinical trial data on approved and emerging JAK inhibitors in this setting, and the importance of considering JAK inhibitors when creating patient-specific plans for patients with inadequately controlled AD.
What role do biomarkers play in Alzheimer’s disease (AD)? The availability of a new pharmacologic class for AD offers the potential for disease modification when added early in the disease course, emphasizing the importance of novel biomarkers. In this podcast, experts review the association between biomarkers and symptoms of AD, the use of biomarkers for the early detection of AD, and the potential of available and emerging disease-modifying therapies for AD.
Join experts to learn more about vasomotor symptoms of menopause – contributing factors, undertreatment, current treatment options, and emerging therapies with novel targets.
Are you aware of the strong association between dry eye disease (DED) and meibomian gland dysfunction (MGD)? Recent evidence demonstrates that DED is most often associated with MGD. Moreover, many risk factors, signs, and symptoms overlap, which complicates patient care. Join Eric D. Donnenfeld, MD, in this 30-minute educational podcast as he offers valuable insights on this association, as well as the evidence-based protocol for assessment, diagnosis, and proper disease management.
Drs Jessica Ailani and Susan Hutchinson examine how to individualize migraine preventive therapy based on patient preferences as well as relevant clinical data and consensus recommendations.
This program will address the evolving concepts of pathophysiology, diagnosis, and severity assessment of patients across a diverse spectrum of age, comorbidities, and skin of color. In conjunction, the role of new and emerging targeted therapy agents will be examined within the context of mild to severe AD.
Are you confident using novel agents for acute myeloid leukemia (AML) in your practice? Listen to faculty experts discuss challenging patient cases and provide guidance on using new agents, creating individualized treatment plans, monitoring adverse events, and the role of measurable residual disease in AML management.
In this 15-minute activity, Dr W. Clay Jackson will identify common barriers to achieving recovery in major depression, and evidence-based strategies to overcome these barriers in your patients.
In this 15-minute activity, Dr W. Clay Jackson will review strategies to address treatment-resistant major depression, including switching, augmenting, and combining therapies.